Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Its product candidates include UNLOXCYTTM (cosibelimab-ipdl) for the treatment of adults with metastatic cSCC or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Additionally, the Company is engaged in evaluating its lead investigational small-molecule, targeted anti-cancer agent, olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Market Cap	371M 324M 299M 276M 524M 35.36B 533M 3.57B 1.4B 17.42B 1.39B 1.36B 59.88B	P/E 2023	-1.23x	P/E 2024	-2.26x
Enterprise Value	364M 318M 294M 271M 515M 34.73B 523M 3.51B 1.38B 17.11B 1.37B 1.34B 58.81B	EV / Sales 2023	475x	EV / Sales 2024	3,650x
Free-Float	47.41%	Yield 2023 *	-	Yield 2024	-

25-06-01	Checkpoint Therapeutics, Inc.(NasdaqCM:CKPT) dropped from S&P TMI Index	CI
25-05-30	Sun Pharmaceutical Industries Limited completed the acquisition of Checkpoint Therapeutics, Inc. from Fortress Biotech, Inc., Armistice Capital Master Fund Ltd., managed by Armistice Capital LLC and others.	CI
25-05-30	Sun Pharmaceutical Industries Completes Acquisition Of Checkpoint Therapeutics	RE
25-05-30	Fortress Biotech Closes Sale of Checkpoint Therapeutics Unit	MT
25-05-30	Checkpoint Therapeutics, Inc. Appoints Zvi Albert as Chief Financial Officer	CI
25-05-30	Checkpoint Therapeutics, Inc. Announces Board and Executive Changes	CI
25-05-29	Checkpoint Therapeutics, Inc.(NasdaqGM:CKPT) dropped from NASDAQ Composite Index	CI
25-05-13	Checkpoint Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-28	Checkpoint Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-27	Checkpoint Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
25-03-11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
25-03-10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
25-03-10	Checkpoint Therapeutics to Be Acquired by India's Sun Pharmaceutical -- Checkpoint Shares Jump Monday	MT

25-03-11	HC Wainwright Downgrades Checkpoint Therapeutics to Neutral From Buy, $20 Price Target	MT
25-03-10	Lake Street Downgrades Checkpoint Therapeutics to Hold From Buy, $4.10 Price Target	MT
23-12-20	B. Riley Lowers Checkpoint Therapeutics' Price Target to $4 From $8, Keeps Buy Rating	MT
23-08-22	B. Riley Lowers Checkpoint Therapeutics' Price Target to $8 From $15, Keeps Buy Rating	MT
23-08-15	Lake Street Adjusts Checkpoint Therapeutics Price Target to $14 From $16, Maintains Buy Rating	MT

25-05-30	Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics	AQ
25-05-13	Checkpoint Therapeutics Reports First Quarter Financial Results and Recent Corporate Updates	AQ
25-04-29	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU
25-03-28	Checkpoint Therapeutics Reports Full-Year 2024 Financial Results and Recent Corporate Updates	AQ
25-03-14	CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT	BU

24-08-22	Avery Dennison Corporation : Todo lo que busca
24-07-18	Zscaler, Inc.: de kunst van de Zero Trust-aanpak
24-07-17	Zscaler: l'arte dell'approccio zero trust
24-07-16	Zscaler, Inc.: El arte del enfoque de confianza cero
24-07-16	Zscaler : l'art de l'approche zero trust

Checkpoint Therapeutics Inc Stock Other OTC

Stocks

US1628281073

Biotechnology & Medical Research

Valuation: Checkpoint Therapeutics Inc

Latest news : Checkpoint Therapeutics Inc

Analysts' recommendations: Checkpoint Therapeutics Inc

Press Releases: Checkpoint Therapeutics Inc

News in other languages: Checkpoint Therapeutics Inc

Quotes and Performance

Managers and Directors: Checkpoint Therapeutics Inc

Bio Therapeutic Drugs

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CHECKPOINT THERAPEUTICS INC	-0.50%	+2.05%	-	-	357M
WUXI APPTEC CO., LTD.	+1.84%	-0.66%	+59.82%	+92.96%	54.88B
ARGENX SE	-4.14%	-8.06%	+58.96%	+118.67%	54.63B
INSMED INCORPORATED	-2.24%	+3.59%	+17.75%	+477.47%	25.06B
BIONTECH SE	-1.60%	-6.21%	-18.96%	-15.21%	23.14B
WUXI BIOLOGICS (CAYMAN) INC.	+2.43%	+1.06%	+42.44%	-1.27%	19.88B
GENMAB A/S	-3.19%	0.00%	+35.60%	-26.98%	17.55B
PHARMAESSENTIA CORPORATION	-6.84%	+2.18%	+195.12%	+357.18%	16.5B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+8.74%	+3.51%	+51.91%	+726.40%	15.36B
EXELIXIS, INC.	-1.05%	+1.16%	+25.95%	+194.27%	14.2B
Average	-0.66%	-0.28%	+52.07%	+213.72%	26.8B
Weighted average by Cap.	-0.91%	-1.46%	+51.26%	+176.25%

	2023	2024
Net sales	103K 90.09K 83.1K 76.75K 146K 9.82M 148K 993K 390K 4.84M 387K 378K 16.64M	41K 35.86K 33.08K 30.55K 57.97K 3.91M 58.95K 395K 155K 1.93M 154K 151K 6.62M
Net income	-51.85M -45.35M -41.83M -38.63M -73.31M -4.94B -74.54M -500M -196M -2.44B -195M -190M -8.37B	-56.24M -49.19M -45.37M -41.91M -79.52M -5.36B -80.86M -542M -213M -2.64B -211M -207M -9.08B
Net Debt	-4.93M -4.31M -3.98M -3.67M -6.97M -470M -7.08M -47.51M -18.66M -232M -18.5M -18.1M -796M	-6.6M -5.78M -5.33M -4.92M -9.34M -630M -9.49M -63.66M -25M -310M -24.8M -24.26M -1.07B